Andon Health, which supplies Covid test kits both at home and abroad, reported that its net profit skyrocketed by 27,728% in the first six months of 2022, reaching 15.24 billion yuan ($2.2 billion). It was the biggest increase recorded by any listed company in mainland China.
Meanwhile, its revenue surged 3,989%.
The company benefits not only from China’s aggressive testing campaign at home, but also from huge demand in the United States, as its iHealth Lab had recently won US government contracts for supplying antigen rapid tests.
Assure Tech, a Hangzhou-based diagnostic firm, also posted a 1,324% increase in net income because of strong demand in the global Covid testing market.
Other test makers recorded net profit increases from 55% and 376% for the first six months of the year.
Chinese companies have also suffered one of their worst earnings recessions on record. More than half of the 4,800 companies listed in Shanghai, Shenzhen, and Beijing posted a decline in net profit for the first half of the year — almost as bad as early 2020, when most companies posted their worst earnings season ever.
But the diagnostic firms are one of the biggest moneymakers during the pandemic, benefiting from enormous demand for testing as Beijing sticks with its zero-Covid policy that involves forced quarantines, mass mandatory testings, and snap lockdowns.
From the beginning of the pandemic through April 2022, 11.5 billion tests had been conducted in China, according to the government.
That figure may have significantly increased since then, as analysts from Soochow Securities recently estimated that 10.8 billion tests had been conducted in the three months from April to June.
The costs may be a big burden on the Chinese government’s finances, which have already taken a hit from collapsing property sales. In May, officials in Beijing made it clear provincial and city governments had to bear the costs for regular Covid testing.
Assuming big Chinese cities that account for 30% of the population conduct Covid tests twice a week, the direct cost of testing may total 200 billion yuan ($30.1 billion) from May to the year’s end, according to an estimate by Goldman Sachs earlier this year.
The number could rise further if the remaining 70% of the population is tested and costs of setting up testing sites and quarantine centers are taken into account, Goldman Sachs said.